How Is GSK Plc (LSE:GSK) Trading Today?

GSK Plc (LSE:GSK) shares edged higher by 0.08% to around 1,902.5p today, following third-quarter results on 28 October 2026 in which the pharmaceutical group reaffirmed its full-year guidance.

Total sales were £8.9 billion, up 4% at actual exchange rates and 5% at constant exchange rates, with Specialty Medicines sales rising 15% to £3.9 billion. Core operating profit rose 5% to £3.08 billion, and cash generated from operations was £3.1 billion, with free Cash Flow of £2.1 billion.

The company declared a third-quarter Dividend of 17p per share and expects a full-year dividend of 70p.

About GSK Plc

GSK is a global biopharma company that discovers, develops and manufactures vaccines and specialty and general medicines. Its portfolio covers HIV, respiratory, immunology and inflammation, oncology, vaccines and established medicines, serving patients in markets around the world.

The company is led by Chief Executive Luke Miels, who took over at the start of 2026 and has set out a focus on launches, late-stage pipeline delivery and reallocation of resources to the highest-value opportunities.

LSE:GSK therefore offers exposure to innovation in medicines and vaccines.

The group operates a global Manufacturing and Supply network and invests heavily in science, with a focus on the immune system, genetics and advanced technologies. This approach is intended to prevent and treat disease at scale and to bring new Options to patients across many therapy areas.

Q3 2026 Performance

HIV sales rose 10% to £2.1 billion, Respiratory, Immunology and Inflammation sales rose 21% to £1.1 billion and Oncology sales rose 23% to £0.6 billion. General Medicines sales were stable at £2.4 billion, with Trelegy up 8% to £0.8 billion, and Vaccines sales were £2.6 billion, with meningitis vaccines up 12%.

Core operating profit growth reflected higher sales, a favourable product and regional mix and higher Royalty income, partly offset by increased Investment in R&D and new asset launches.

2026 Guidance

GSK reaffirmed its 2026 guidance at constant exchange rates, with expected turnover growth of 3% to 5%, and core operating profit and core EPS growth of 7% to 9%. Turnover and core operating profit are expected in the upper half of their ranges, and Specialty Medicines is expected to increase at a low double-digit rate.

The group remains on track for its 2031 sales outlook of more than £40 billion, and it expects Operating Margin to be stable to improving through the dolutegravir loss of exclusivity period of 2028 to 2030.

Pipeline Progress

The company is on track to start 22 phase III trials this year, with 18 started so far. Recent regulatory milestones included approvals for Hibsago in the US and Japan and for Jemperli in the US, and a Shingrix pre-filled syringe was approved in Japan.

An mRNA seasonal flu phase III trial has also begun, and positive data have been reported in areas such as ovarian and lung cancer.

Late-stage programmes span infectious disease, respiratory, oncology and immunology. Management has emphasised that clinical delivery, regulatory submissions and timely launches are the main drivers of long-term growth, with each milestone adding to the visibility of the medium-term sales outlook.

Shareholder Returns

GSK completed its £2 billion share buyback programme in the second quarter of 2026. The dividend policy and expected Payout Ratio are unchanged, with a full-year 2026 dividend of 70p expected.

Year-to-date free cash flow of £4.9 billion was £1.8 billion higher than a year earlier, supporting both investment and returns.

Growth Catalysts

Possible catalysts for LSE:GSK include launches of new medicines, expansion of long-acting HIV treatments, growth in respiratory and oncology products and late-stage pipeline readouts. Business development and partnerships may add further options.

The group has indicated that its Tariff relief agreement with the US Government is included within its guidance.

Vaccines remain a significant part of the portfolio, with meningitis, shingles and respiratory syncytial virus products serving large patient populations. Demand for long-acting HIV treatment options also gives the group a differentiated position in a category where adherence and convenience are valued.

Factors to Monitor

Pharmaceutical results are influenced by regulatory decisions, trial outcomes, pricing, currency movements, tariffs and Patent timelines. Interest costs following recent acquisitions can influence Earnings Per Share growth.

Investors typically follow sales growth by franchise, margins, pipeline milestones and guidance updates.

Conclusion

GSK's 0.08% gain to around 1,902.5p today follows third-quarter sales of £8.9 billion, 15% growth in Specialty Medicines and reaffirmed 2026 guidance.

HIV, oncology, respiratory, pipeline delivery and cash returns remain the central themes for LSE:GSK.

For investors following LSE:GSK, the combination of reaffirmed guidance, cash generation and a deep late-stage pipeline provides a clear framework for assessing progress at each reporting date.